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Human induced pluripotent stem (IPS) cells overcome several disadvantages of human embryonic stem cells, including host specificity and ethical issues. Patient-specific IPS cells can be generated from every donor by using different cell types, 
making them a suitable tool for autologous cell therapy and tissue engineering. IPS cells generated from patients with genetic 
disorders capture the disease genotype in the cell, making them a good model for studying the pathology of the disease, especially 
during development, and testing different therapeutic approaches. FSHD is one of the most common inherited myopathies, caused 
by a contraction within a subtelomeric array of D4Z4 repeats 4q35.2. It is characterized by uneven and progressive weakness 
and atrophy of facial, shoulder and upper arm muscles. The D4Z4 repeat contains an intronless double homeobox gene named 
DUX4 (double homeobox, chromosome 4) which was recently shown to be expressed specifically in FSHD myoblasts, but not in 
unaffected control cells. DUX4 expressed in high levels induced rapid cell death and in the low levels interferes with myogenesis 
by missregulating MoyD and Myf5. Myoblasts expressing DUX4 failed to fuse and form terminally differentiated myotubes. We 
generated IPS from myoblasts and fibroblast from seven FSHD patients and five controls using four reprogramming factors, Sox2, 
Klf4, Oct4 and c-Myc. IPS cells were characterized by analyzing expression of pluripotent markers and formation of teratomas. 
From IPS cells we generated mesenchymal stem cells using EB culturing system and mesoderm inducing growth factors. 
Mesenchymal stem cells express specific surface markers including CD73 and CD105, and under specific condition were able for 
adipogenic and osteogenic differentiation. To induce myogenesis IPS-MSC we transfected with Myod or Myf5. Stably transfected 
cells were able to expand as myoblasts in myogenic proliferation medium. Generated myoblasts express specific marker CD56 
and under differentiation condition in growth factor deprived medium were able to fuse and terminally differentiate in myotubes. 
Myoblasts generated from IPS cells transplanted in MDX mice were able to engraft and restore dystrofine expression.
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